Q2 2018 13F Holders as of 6/30/2018
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
295M
-
Number of holders
-
209
-
Total 13F shares, excl. options
-
64.7M
-
Shares change
-
+7.74M
-
Total reported value, excl. options
-
$919M
-
Value change
-
+$102M
-
Put/Call ratio
-
1.07
-
Number of buys
-
131
-
Number of sells
-
-80
-
Price
-
$14.20
Significant Holders of SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) as of Q2 2018
260 filings reported holding SGMO - SANGAMO THERAPEUTICS, INC - Common Stock as of Q2 2018.
SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) has 209 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 64.7M shares
of 295M outstanding shares and own 21.97% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (8.16M shares), BlackRock Inc. (8.08M shares), STATE STREET CORP (6.08M shares), WASATCH ADVISORS INC (4.06M shares), FMR LLC (3.32M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (3.25M shares), CREDIT SUISSE AG/ (1.77M shares), EcoR1 Capital, LLC (1.51M shares), Casdin Capital, LLC (1.4M shares), and NORTHERN TRUST CORP (1.29M shares).
This table shows the top 209 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.